MEMORANDUM DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE PUBLIC HEALTH SERVICE FOOD .AND DRUG ADMINISTRATION TO Robert M.
refid# Y0ybo4ObNQwKGXvz1Rd0wZNn2 pages
0r.
refid# qdMwByR3X9d52DDxdDeG6OzgM1 page
t April 5, 1995 David A, Kessler, H.D.
refid# qkJ7n0zyRJ4m8Rgd7QBQXdvnR2 pages
UXICOLOGY a n d a p p l ie d p h a r m a c o l o g y 99, 377-383 (1989) CONTEMPORARY ISSUES IN TOXICOLOGY Establishing Aerosol Exposure Concentrations for Inhalation Toxicity Studies T r e n t R .
refid# 2jGZVb5m09dBdZ2xjKmzpgK367 pages
Toxicology Long-Term Retention and Clearance of Particles Inhaled by Mammalian Species Morris B.
refid# KR0k399ZzgoGV0L1wGEK89mL637 pages
uon DOMESTIC OPERATING COMPANY N E W B R U N S W I C K , N.
refid# 3NZqLyv78o7pL32vxowao9Gjn3 pages
DEPARTMENT OF h -LTH & HUMAN SERVICES Date From June 6, 1985 QRAC (Quantitative Risk Assessment Committee) l- C c PubJ.c Heefth Service Memorandum Subject Asbestos in Talc To W.
refid# KD3jj7XE08VXzkVok7d1Jorr11 pages
j-ixJj.
refid# VJ56gQ5bD2813NYrJEGVO1XbN18 pages
FILE NAME: Talc (TALC) DATE: 1972 May 15 DOC#: TALC068 DOCUMENT DESCRIPTION: Letter from the Center for Science the Public Interest to Barry Castleman (202) 833-3721 CENTER FOR SCIENCE IN THE PUBLIC INTEREST 1346 Connecticut Avenue, N.W., Room 812 Washington, D.C. 20036 Barry Castleman Technical Services Section Division of Air Pollution Industrial Hygiener Bureau of Environmental Services Baltimore Co Dept, of Health Towson, MD 21204 May 15, 1972 Dear Barry: Thanks for writing and showing your interest in the talc and asbestos question.
refid# XRa285RxXppgy8pVEjg7k70bg2 pages
FILE NAME: Talc (TALC) DATE: 2006 DOC#: TALC172 DOCUMENT DESCRIPTION: Published OSHA Information RE Talc Talc (Coiiaming tfsestos) ...........................................-- ... .................................................. ........................ ........ -- -------------- ------------------------- ------- -------------------------------------------------------------------- -- -n C h e m ic a l Sampling Information Talc (Containing asbestos) 4 Chemical Samplinq Information - Table of Contents Field Definitions Analytical Methods Health Guidelines General Description NAME: Talc (Containing asbestos) SYNONYM(s): Talc, Fibrous Tremolite (see Asbestos) prior to 9/1/89 IMIS: 9031 CAS: 14807-96-6 DESCRIPTION: Solid Exposure Limits OSHA GENERAL INDUSTRY PEL: Cancer & Lung Disease Hazard (29 CFR 1910.1001) .
refid# KRroD0mXQO2vgV6VjaZVk2N3N3 pages
FILE NAME: Talc (TALC) DATE: 2006 DOC#: TALC172 DOCUMENT DESCRIPTION: Published OSHA Information RE Talc Talc (Coiiaming tfsestos) ...........................................-- ... .................................................. ........................ ........ -- -------------- ------------------------- ------- -------------------------------------------------------------------- -- -n C h e m ic a l Sampling Information Talc (Containing asbestos) 4 Chemical Samplinq Information - Table of Contents Field Definitions Analytical Methods Health Guidelines General Description NAME: Talc (Containing asbestos) SYNONYM(s): Talc, Fibrous Tremolite (see Asbestos) prior to 9/1/89 IMIS: 9031 CAS: 14807-96-6 DESCRIPTION: Solid Exposure Limits OSHA GENERAL INDUSTRY PEL: Cancer & Lung Disease Hazard (29 CFR 1910.1001) .
refid# 5kQwvo9R6yGdDN9wGvr9E8DkD3 pages
101 1 buying a pig in a poke, you have to believe in the basic 2 integrity of the thing and in the observations and all kinds 3 of things, which you never do get to check, which is sort of 4 why the robustness of the findings and anything that can 5 make it seem less dependent on day-to-day differences adds 6 to the persuasiveness for me, and the things you cited, the 7 evidence of control group, the knowledge that there is 8 quality control in the system that generated the data, all 9 those things certainly help us. 10 CHAIRMAN BUNN: For the consumers on the 11 Committee, one of the things when the FDA approves an agent, 12 it allbws a manufacturer to market or advertise, you know, 13 their product, whereas, they are not allowed to do that 14 without the FDA approval. 15 Most of the time when a company comes in with an 16 extra indication, it is because they feel it is important to 17 advertise or market, and that has been the case in the past. 18 Now we have these new things where companies are just 19 denying drugs, saying, well, the FDA hasn't approved it, 20 therefore, we are not going to pay for it, and that is an 21 unfortunate thing that I think consumers and physicians, 22 even the FDA, as we have just heard, is really not in favor 23 of that type of approach to medical care. 24 DR.
refid# Yjo6JMno1aVbKYyDnwYb7a5D100 pages
.
refid# kadwyMaMDNn6Rry65jvo46GGy100 pages
HOW TO USE THESE SEPARATORS Use one page fo r each sep aration .
refid# j49JRJpG9wp11enQN0GOLz7R3 pages
Pall offers users of process fluids in all parts of the world the broadest range of filter media available for solving fluid clarification problems.
refid# VG1M5GEjrxO4KBb4X8M8ynJYq29 pages